A temperature-setting gel kept transplanted mitochondria working after spinal cord injury — in rats
Edited by Samael A. Tejada, Founder & Editor-in-Chief
·Tip: press play, then lock your phone or switch apps — the article keeps reading.
An injectable gel that sets at body temperature protected transplanted mitochondria and kept them in place after spinal cord injury, restoring spinal cord mitochondrial respiration to uninjured levels at 48 hours in rats (ACS Applied Bio Materials, November 12, 2026). It is a preclinical delivery result — no human testing is involved.
Mitochondrial transplantation has a logistics problem: the organelles are fragile, and an injection that disperses helps no one. This team engineered the shipping container — a gel that thickens exactly where it is delivered.
How does the gel work?
The carrier is hyaluronic acid — a biocompatible molecule the body already makes — chemically grafted with poly(N-isopropylacrylamide), a polymer that collapses and thickens above a transition temperature. The resulting semi-gels are injectable, thicken at the delivery site so they resist dispersion under flow, and dissolve over hours, releasing the mitochondria they carry. The team built a library of versions and characterised their composition, phase behaviour, flow properties and release timing.
Did the cargo survive — and did it work in animals?
Encapsulation preserved mitochondrial respiratory function and membrane potential relative to free mitochondria over the delivery-relevant time window. In the animal test — a contusion spinal cord injury in adult female Sprague-Dawley rats, with mitochondria delivered under the dura — transplantation in the gel restored both State III and State V-II respiration in injured spinal cord to levels not distinguishable from uninjured controls at 48 hours post-injury.
What are the limits?
Forty-eight hours is a respiration measurement, not a recovery outcome: the paper does not show the rats regained movement or function, and mitochondrial transplantation itself remains an experimental strategy with open questions about sourcing, dosing and durability. What this study adds is a tunable, cell-compatible delivery platform — the piece of the puzzle that has to work before functional questions can even be asked properly.
Frequently asked questions
What is mitochondrial transplantation?
An experimental approach that delivers healthy mitochondria, isolated from donor tissue, into injured or dysfunctional tissue in the hope they restore cellular energy production. It is not an approved treatment for any condition.
Why does the carrier matter?
Free mitochondria are fragile and disperse quickly. A carrier that protects them and holds them at the injury site addresses two of the main reasons earlier delivery attempts underperformed.
Has this been tried in people?
Not for spinal cord injury in this study — the work is in rats, at a 48-hour laboratory endpoint.
Where the evidence stands
- Established: Mitochondrial transplantation is an actively researched strategy for conditions involving mitochondrial dysfunction, and transplanted mitochondria lose function quickly when delivered unprotected.
- Preliminary: The gel platform: one preclinical study (ACS Applied Bio Materials, 2026) in rat spinal cord injury, with a 48-hour respiration endpoint.
- Absent: Evidence of functional recovery in animals, and any human safety or efficacy data for mitochondrial transplantation in spinal cord injury.
Join the discussion
To get the conversation started: What questions does this story raise for you? Share them below — every comment is reviewed by our moderators before it appears.
Community discussion only — not medical advice. Every comment is reviewed by our moderators before it appears. Sign in with Google or a free Hyvor account to join in.